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Aims: Novel oral iron supplements may be associated with a reduced incidence of
adverse drug reactions compared to standard treatments of iron deficiency anaemia.
The aim was to establish their value-based price under conditions of uncertainty
surrounding their tolerability.
Methods: A discrete-time Markov model was developed to assess the value-based
price of oral iron preparations based on their incremental cost per quality-adjusted
life year (QALY) gained from the perspective of the NHS in the UK. Primary and sec-
ondary care resource use and health state occupancy probabilities were estimated
from routine electronic health records; and unit costs and health state utilities were
derived from published sources. Patients were pre-menopausal women with iron
deficiency anaemia who were prescribed oral iron supplementation between 2000
and 2014.
Results: The model reflecting current use of iron salts yielded a mean total cost to
the NHS of £779, and 0.84 QALYs over 12 months. If a new iron preparation were to
reduce the risk of adverse drug reactions by 30–40%, then its value-based price,
based on a threshold of £20 000 per QALY, would be in the region of £10–£13 per
month, or about 7–9 times the average price of basic iron salts.
Conclusions: There are no adequate, direct comparisons of new oral iron supple-
ments to ferrous iron salts, and therefore other approaches are needed to assess
their value. Our modelling shows that they are potentially cost-effective at prices
that are an order of magnitude higher than existing iron salts.
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1 | INTRODUCTION
Iron deficiency is the most common cause of anaemia worldwide1,2
and, for uncomplicated cases, it is treated with oral iron supplementa-
tion. In England, 7.98 million prescriptions for oral iron were dis-
pensed in the community in 2018, and >99% of these were in the
form of simple iron salts, typically sulfate, gluconate or fumarate.3
These are effective and inexpensive (£1.38 per 28 tablets) but adverse
drug reactions (ADRs) occur in about a third of patients. Common
ADRs are gastrointestinal and include nausea, vomiting and
constipation,4 and these lead to frequent dose adjustments, change in
prescription, non-adherence or treatment discontinuation. As a result,
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the true cost of prescribing “inexpensive” iron salts may be signifi-
cantly higher than the cost of the product itself, owing to associated
increases in the utilisation of health care services. In turn, this has
prompted the development of novel oral iron forms that seek to
reduce ADRs or a switch away from oral iron to intravenous strate-
gies.5,6 Both alternative approaches are markedly more expensive
than oral iron salts but the key issue concerns the pricing at which
they would become cost-effective.
A meta-analysis of 20 randomised controlled trials identified a rel-
ative risk of 1.59 (95% confidence interval [CI] 1.43–1.76) for gastro-
intestinal ADRs to ferrous sulfate versus placebo.4 Therefore, given
that approximately one third of patients taking oral iron experience
ADRs (29.9% for ferrous gluconate, 30.2% for ferrous sulfate and
43.4% for ferrous fumarate),7 an absolute 12% of all patients pre-
scribed common iron salts might avoid gastrointestinal ADRs if an
ideal treatment were available. Indeed, quite a number of alternative
iron preparations, either on the market or in the pipeline, claim to have
superiority over ferrous iron salts in terms of acute, gastrointestinal
ADRs. Gastrointestinal intolerance is generally considered to relate to
the oxidation of ferrous iron in the gut lumen following iron ingestion,
and the generation of damaging reactive oxygen species. To avoid this,
iron may be chelated, potentially in its ferrous form (e.g., iron bis-gly-
cinate8) or, most commonly, as ferric iron (e.g., ferric maltol, ferric cit-
rate, ferric EDTA9,10). This not only helps to maintain iron in a soluble
form but also opposes the drive for iron redox cycling in the intestine.
An alternative approach involves oral delivery of iron as a nanoparticle
(e.g., iron hydroxide adipate tartrate11) which also prevents luminal
redox activity and delivers a bolus dose to the enterocyte lysosome,
which is a safe house for iron dissolution, recycling and systemic
absorption. Finally, an approach that is a hybrid of the two mecha-
nisms described above has also been proposed with sucrosomial iron,
which consists of ferric pyrophosphate coated with a lecithin and
sucrose esters. This is absorbed as sucrose ester conjugates and parti-
cles or vesicle-like structures.9 With all these potential therapeutic
options, decision-making for the prescriber is clearly challenging.
A key determinant for informing decisions concerning the pre-
scribing of medicines is their cost-effectiveness. The National Health
Services (NHS) in the UK operate a threshold in the range of £20 000
to £30 000 per quality-adjusted life year (QALY) gained, below which
medicines are considered to represent good value for money.12 It fol-
lows that the value-based price of new medicines may be established
from knowing the health gains—such as reduction in ADRs—that can
be achieved. A medicine priced up to its value-based price would con-
sequently be cost-effective.13
The aim of this study was to estimate the value-based price,
centred on the cost per QALY as a measure of value to the NHS, of
oral iron therapies seeking to replace simple oral iron salts.
2 | METHODS
A cost-utility analysis was performed from the perspective of the NHS
in the UK to estimate the value-based price of a hypothetical new iron
therapy as an alternative to inexpensive ferrous iron salts for the man-
agement of iron deficiency anaemia in adult patients. A decision ana-
lytic model was developed, with probabilities of transitioning among six
health states relevant to the management of iron deficiency anaemia
based on data obtained from the Clinical Practice Research Datalink
(CPRD); utilities based on EuroQol (EQ)-5D-3L tariff scores; and direct
medical costs of primary and secondary care services based on CPRD
and linked Hospital Episode Statistics (HES) data. The health economic
analysis was conducted over a 12-month time horizon. The model had
a cycle length of 60 days and a half cycle correction was applied.
2.1 | CPRD and HES data
The analysis used the CPRD-GOLD database of anonymised, longitu-
dinal, primary care clinical data contributed by general practices from
across the UK. CPRD had a coverage of over 11.3 million patients
from 674 practices in the UK in 2013, and has been validated to be
representative of the UK population for age, sex and ethnicity.14 The
CPRD allows access to linked HES data from NHS Digital. This admin-
istrative dataset records all NHS England hospital inpatient admis-
sions, including combined day case and ordinary elective spells.
The protocol for this study (reference number 14_201) was
approved scientifically and ethically by the CPRD Independent Scien-
tific Advisory Committee.
2.2 | Study population and treatments
The CPRD was accessed to identify female patients, aged between
18 and 45 years (i.e., typically pre-menopausal) who were prescribed,
What is already known about this subject
• Novel oral iron supplements may be associated with a
reduced incidence of adverse gastrointestinal reactions
but they might not be cost-effective compared with inex-
pensive iron salts.
What this study adds
• This analysis provides a framework for setting prices
according to incidence of adverse drug reactions, and
suggests that novel oral iron supplements could be cost-
effective at prices that are several-fold higher than exis-
ting oral iron salts.
• Estimates of the value-based prices of drugs in develop-
ment provide a basis for assessing commercial viability,
while also assisting the healthcare payers in their horizon
scanning activities.
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between January 2000 and October 2014, at least one of the top six
iron products (which were all ferrous salts) by dispensing volume from
the prescription cost analysis database.15 The product codes for these
in CPRD are: dried ferrous sulfate tablets 200 mg (33); ferrous fuma-
rate tablets 210 mg (3035); ferrous gluconate tablets 300 mg (712);
ferrous fumarate tablets 322 mg (2915, 3151); ferrous fumarate cap-
sules 305 mg (5045, 6052); and dried ferrous sulfate MR tablets
325 mg (1745, 5582). A course of treatment was defined by a new
prescription of oral iron distinct from the immediate previous oral iron
prescription (by type or by dose), or a prescription of the same oral
iron dated more than 2 months after the previous prescription date.
2.3 | Health states
CPRD and HES data were used to estimate the probabilities of
patients residing in each of six mutually exclusive health states,
defined by their response and tolerance to treatment (Table 1). The
following health states regarding anaemia improvement at assess-
ments (haemoglobin test taken or hospitalisation) within a course of
treatment were defined: no improvement of haemoglobin with/
without treatment tolerance (States 1 and 3); improvement of
haemoglobin with/without treatment tolerance (States 2 and 4); hos-
pital referral (State 5); anaemia resolved (State 6). Further definitions
of haemoglobin improvement are provided in the Appendix in the
Supporting Information.
Patients were considered intolerant of iron supplementation if
their primary or secondary medical records indicated treatment cessa-
tion coinciding with a potential ADR (using Read codes for symptoms
such as constipation, diarrhoea, nausea, heartburn), a reduction in
daily dose or a change in product class. Treatment intolerance was
ascertained for each course of treatment and was therefore time-
invariant within a given course of treatment.
2.4 | Transition probabilities
A previously described discrete-time Markov model with multinomial
logistic regression was used to estimate transition probabilities
between health states16 (see Appendix in the Supporting Information).
This was simplified for the economic analysis by averaging the
probabilities across doses and treatment courses to provide a single
matrix of time-dependent state occupancy probabilities (Table 1). The
Markov model is depicted schematically in Figure 1.
2.5 | Health state utilities
Health state utilities were derived from a purposive review of the lit-
erature (see Appendix in the Supporting Information).
For the “no improvement & tolerant” health state, utilities were
assumed to be represented by data from a study of iron treatment for a
population of 236 women with heavy menstrual bleeding (mean base-
line Hb 11.0 g/dL).17 This study reported a mean baseline EQ-5D utility
score of 0.76. In the absence of any specific evidence, this utility value
was also applied to the “improvement & intolerant” health state, on the
assumption that the health effects of an improvement in iron deficiency
is offset by the adverse reaction to the iron supplementation.
Peuranpää et al.17 reported an improvement in Hb at 12 months
of 1.2 g/dL following iron supplement intake. The corresponding util-
ity (0.85) was assumed for the “improvement & tolerant” health state.
The disutility associated with being treatment-intolerant was
determined from a trial of adult patients with iron-deficiency anaemia
and who had failed, or were intolerant to, oral iron therapy.18 Sum-
mary responses to the SF-36 were converted to EQ-5D-3L utilities,19
which necessitated data to be extracted by digitising figures using
WebPlotDigitizer.20 The difference in EQ-5D-3L utility of 0.04
between baseline (mean Hb of 8.9 g/dL) and the end of follow-up
(mean Hb of 11.7 g/dL), was subtracted from 0.76 to estimate the
utility of the “no improvement & intolerant” health state, as 0.72.
For the “hospital state” utility value, International Classification
of Diseases (ICD)-10 codes obtained from HES data were converted
to ICD-9 in order to estimate the marginal disutility.21 This was
based on UK preference scores applied to EQ-5D descriptive
questionnaire responses in relation to 135 chronic, ICD-9 coded
conditions in the US-based Medical Expenditure Panel Survey, and
controlled for gender, age and ethnicity. The mean disutility score
for iron deficiency anaemia of 0.036 was subtracted from the
“no improvement & tolerant” health state utility score, resulting in a
mean utility score for the “hospital state” of 0.72.





















60 days 0.1880 0.1572 0.3239 0.0518 0.0045 0.2746
120 days 0.0958 0.1426 0.2277 0.0631 0.0230 0.4476
180 days 0.0600 0.1145 0.1718 0.0630 0.0295 0.5612
240 days 0.0427 0.0916 0.1365 0.0590 0.0293 0.6408
300 days 0.0327 0.0745 0.1126 0.0540 0.0266 0.6996
360 days 0.0261 0.0615 0.0954 0.0489 0.0235 0.7445
420 days 0.0214 0.0515 0.0825 0.0442 0.0206 0.7798
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The health utility for the state of “anaemia resolved” was based
on UK population norms.22 A utility score of 0.90 was calculated from
the mean of utility scores of 0.93, 0.91 and 0.85 reported for women
in the age categories of 25–34, 35–44 and 45–54 years, respectively.
2.6 | Resource use and costs
CPRD data were used to identify patients' prescribed iron supplemen-
tation, blood tests and visits to the general practitioner (GP). Linked
HES data were available for 139 069 patients of the sample of
254 262 patients. These were filtered to include only observations
that occurred in one health state at any one time, resulting in 30 541
participants. HES data were used to identify inpatient and outpatient
hospital attendances.
The unit costs of medicines were sourced from the British
National Formulary (BNF),23 and the total cost calculated by multiply-
ing the cost for the daily quantity of iron supplement by the number
of days of treatment per patient.
The cost of a haemoglobin test (£3.37) was obtained from the
National Schedule of Reference costs 2015–16 (phlebotomy
Healthcare Resource Group [HRG] code DAPS08), while GP consulta-
tions were costed at £45, based on an average of 11.7 minutes per
consultation24 (Table 2).
Patients who had hospital care (as inpatient stays or outpatient
visits), which occurred within the period they were treated for iron
deficiency, were attributed HRG codes. HRG codes define patients'
episodes of consultant-led hospital care, and spells of hospital admis-
sion and discharge. As HRG codes and costs change over time, all
HRG codes were converted to the 2016–17 National Tariff25
(Table S1 in the Supporting Information). This was accomplished by
attaching a full description of the HRG name or procedure to each
code to ensure they matched and corresponded to the same
procedure across the years. Costs associated with patients' hospital
stays were calculated by continuous inpatient spell, HRG code and
trim day, with the latter taking into consideration the number of days
each patient spent in hospital below (inlier bed days) and above
(excess bed days) the trim point.
2.7 | Cost analysis
The total cost per patient was calculated by summing the cost of pre-
scribed iron preparations, the cost of blood tests, GP consultations
and hospital stays. A cost multiplier was introduced, such that the cost
of “new iron” could range between 1 (= cost of standard iron salts)
and 10 times the cost of existing oral iron preparations.
Given the large sample size, the central limit theorem was
assumed to apply, and health state costs were obtained from the
coefficients of variables included in a linear (ordinary least squares)
regression, specified with total costs as the dependent variable, health




where X = health state and ε is the error term.
2.8 | Base-case analysis
Treatments received by patients in the CPRD sample were assumed
to reflect standard care; while the simulated effect of the intervention
(in the base-case analysis) considered the hypothetical, new iron prep-
aration only for those who resided in the treatment-intolerant health
states.
F IGURE 1 Schematic
depiction of the economic model,
indicating each mutually exclusive
health state, and with transition
probabilities represented by
arrows
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Given the analysis is based on a hypothetical intervention, a
threshold analysis was performed to identify the value-based prices at
which a “new iron” therapy is cost-effective at £20 000 per QALY
gained, by varying the cost of “new iron” (as a multiplier of the mean
cost of existing iron products) for two different probabilities of reduc-
tion in treatment intolerance (30% and 40%). The base-case analysis
therefore established the value-based price of “new iron” which
satisfies:
Costs New_Ironð Þ ¼ λ  QALY New_Ironð Þ –QALY Standard_Careð Þ
 
þCosts Standard_Careð Þ
where Costs(New_Iron) and Costs(Standard_Care) are the total costs to
the NHS associated with new and standard iron preparations,
respectively; and QALY(New_Iron) and QALY(Standard_Care) are the
expected QALYs for the intervention and control groups. λ is the
cost-effectiveness threshold of £20 000 per QALY.
2.9 | Sensitivity analysis
One-way sensitivity analyses were conducted to assess the impact
of varying each health state utility by ± 0.1 on value-based prices
under the base-case scenario of 30% and 40% reduction in the
probabilities of treatment intolerance. These were depicted as
tornado plots. The health utility corresponding to the state of anae-
mia being resolved was not varied as this was based on population
norms.
TABLE 2 Unit cost of iron preparations, general practitioner consultations and phlebotomy
Item of resource use Unit cost (£) Reference
Medicines (per pack of 28)
Fefol Spansules (Intrapharm Laboratories Ltd) 4.25 17
Feospan 150 mg Spansules (Intrapharm Laboratories Ltd) 4.25 17
Ferrograd 325 mg modified-release tablets (Teofarma) 2.58 17
Ferrograd C modified-release tablets (Teofarma) 3.20 17
Ferrograd folic 325 mg/350 μg modified-release tablets (Teofarma) 2.64 17
Ferrous fumarate 140 mg/5 mL oral solution 3.73 17
Ferrous fumarate 140 mg/5 mL oral solution sugar free 3.73 17
Ferrous fumarate 210 mg tablets 3.50 17
Ferrous fumarate 305 mg/folic acid 350 μg capsules 2.33 17
Ferrous fumarate 305 mg capsules 2.33 17
Ferrous fumarate 322 mg/folic acid 350 μg tablets 1.00 17
Ferrous fumarate 322 mg tablets 1.00 17
Ferrous gluconate 300 mg tablets 2.61 17
Ferrous sulfate 150 mg/folic acid 500 μg modified-release capsules 3.95 17
Ferrous sulfate 150 mg modified-release capsules 3.95 17
Ferrous sulfate 160 mg modified-release tablets 3.95 17
Ferrous sulfate 200 mg tablets 2.23 17
Ferrous sulfate 200 mg tablets (A A H Pharmaceuticals Ltd) 2.78 17
Ferrous sulfate 200 mg tablets (IVAX Pharmaceuticals UK Ltd) 2.78 17
Ferrous sulfate 325 mg/ascorbic acid 500 mg modified-release tablets 3.20 17
Ferrous sulfate 325 mg/folic acid 350 μg modified-release tablets 2.64 17
Ferrous sulfate 325 mg modified-release tablets 2.58 17
Fersaday 322 mg tablets (Mercury Pharma Group Ltd) 1.00 17
Fersamal 140 mg/5 mL oral solution (Forley Generics Ltd) 3.73 17
Fersamal 210 mg tablet (Forley Generics Ltd) 3.50 17
Fersamal 210 mg tablets (Mercury Pharma Group Ltd) 3.50 17
Galfer 305 mg capsules (Thornton & Ross Ltd) 2.33 17
Galfer FA capsules (Thornton & Ross Ltd) 2.33 17
Pregaday 322 mg/350 μg tablets (Focus Pharmaceuticals Ltd) 1.25 17
General practitioner consultation (per visit) 45.00 18
Phlebotomy (HRG DAPS08) (per test) 3.37 19
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A two-way sensitivity analysis was performed to estimate the
incremental cost-effectiveness ratio (ICER) for “new iron” versus stan-
dard treatment for different combinations of prices of “new iron” and
probability of being treatment intolerant.
The improved safety of “new iron” was modelled as reductions in
the relative risk of being treatment intolerant (in 5% increments up to
50%) and higher probabilities of being in corresponding treatment-
tolerant states. For instance, a 5% relative decrease in the probability
of being in the “improvement & intolerant” health state required a
corresponding increase in the probability of “improvement & tolerant”.
Similar changes were modelled for the “no improvement & tolerant”
and “no improvement & tolerant” health states. In order for probabili-
ties to sum to 1, they were normalised by sharing any small residual
difference across the six health states.
Threshold analyses were undertaken to test the sensitivity of the
value-based price, assuming a 30% and 40% decrease in the probabil-
ity of treatment intolerance, to changes in health state utilities, costs
and transition probabilities.
2.10 | Probabilistic sensitivity analyses
A probabilistic sensitivity analysis was performed to consider the
joint uncertainty in costs and QALYs. Correlation between cost
parameters in the regression model was preserved using the
Cholesky decomposition of the variance–covariance matrix. Monte
Carlo simulation was conducted to obtain 10 000 correlated draws
from a multivariate normal distribution.26 For utilities, a fixed stan-
dard deviation of 0.2 was assumed, and 10 000 draws made from
independent beta distributions fitted using the method of moments.
Cost-effectiveness acceptability curves were constructed for two
combinations each of the price of “new iron” (5 and 10 times the
price of iron salts) and the probability of treatment intolerance
(reduced by 30% and 40%).27
2.11 | Scenario analysis
A scenario analysis was conducted to estimate the ICERs for “new
iron” versus standard treatment for different prices of “new iron” and
reduced probabilities of being treatment intolerant in the
“hospitalisation” health states in addition to the “no improvement &
intolerant” and “improvement & intolerant” states. As described above,
the probability of treatment tolerance was increased in the
opposite correspondent health states “no improvement & tolerant”,
“improvement & tolerant” and “anaemia resolution”. Probabilities were
again normalised to sum to 1 by distributing small differences equally
across the six health states.
All analyses were conducted using Stata version 13 (StataCorp
2013), Microsoft Excel (2016) and RStudio. The reporting of the eco-
nomic analysis is compliant with the Consolidated Health Economic
Evaluation Reporting Standards.28
3 | RESULTS
3.1 | Resource use and costs
Patients residing in the “no improvement & intolerant”; and “no
improvement & tolerant” states recorded the highest mean number of
GP visits, at 1.08 and 1.03 per 60-day period, respectively, with asso-
ciated mean costs of £48.74 and £46.40. Patients in the “improvement
& tolerant” and “improvement & intolerant” health states recorded 0.99
and 0.94 GP visits per 60-day period, costing £44.37 and £42.21,
respectively. The “anaemia resolved” health state saw the lowest num-
ber of GP visits, at 0.21 with an associated mean cost of £9.63.
Iron supplements were prescribed more frequently to patients
residing in the “no improvement & intolerant” and Hospitalisation
health states with an average of 74.8 and 67.6 doses over the 60-day
interval, respectively, at a mean cost of £7.79 and £7.40. Patients in
the “improvement & intolerant” health state were prescribed 61.7
doses (at a cost of £6.51); while those in the “no improvement & toler-
ant” state 57.9 doses (£5.97), those in the “improvement & tolerant”
state 56.8 doses (£6.20), and those in “anaemia resolved”, 28 doses
(£3.06). Considering patients' time within, and distribution among,
each health state, the mean 1-year cost of iron preparations was
£16.55.
The results of the regression analysis indicated that highest total
costs were associated with patients who had hospital episodes,
reporting a mean 60-day cost of £279.52 (95% CI £257.81–£301.48),
while the least costly health state was “anaemia resolved” at £80.00
(95% CI £46.87–£113.58) (Table 3).
TABLE 3 Health state utilities and 60-day costs
Description Utility (SD) Cost (£) (95% CI)
State 1 No improvement in Hb (<2 g/dL), tolerant to treatment 0.76 (0.2) 141.51 (119.19, 164.00)
State 2 Improvement in Hb (≥2 g/dL), tolerant to treatment 0.85 (0.2) 130.07 (108.34, 152.12)
State 3 No improvement in Hb (<2 g/dL), intolerant to
treatment
0.72 (0.2) 146.68 (125.28, 168.49)
State 4 Improvement in Hb (≥2 g/dL), intolerant to treatment 0.76 (0.2) 165.64 (144.13, 1187.46)
State 5 Anaemia-related hospital admission 0.72 (0.2) 279.52 (257.81, 301.48)
State 6 Resolution (Hb ≥ 12 g/dL) 0.90 (0.2) 80.00 (46.87, 113.58)
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3.2 | Incremental analysis and value-based pricing
The model reflecting current use of iron salts yielded a mean total cost
to the NHS of £779.24 over 1 year, and 0.839 QALYs. Assumed 30%
and 40% relative risk reductions in the likelihood of treatment intoler-
ance with “new iron” resulted in 0.0064 and 0.0086 QALY gains in
comparison with iron salts (Table 4). Threshold analyses indicated that
at the £20 000 per QALY threshold willingness to pay, the price of
“new iron” could increase to 7.30 and 9.44 times that of the basket of
iron salts (£1.38 per 28 tablets) to remain cost-effective with 30% and
40% reductions in treatment intolerance. This is equivalent to £10.07
and £13.02 per 28 tablets (Figure 2). At the higher threshold of
£30 000 per QALY, the value-based prices of “new iron” are 10.20
and 13.33 times the price of iron preparations (equivalent to £14.07
and £18.38 per 28 tablets) for 30% and 40% relative risk reductions in
intolerance, respectively.
3.3 | Sensitivity analyses
The one-way sensitivity analyses indicated that the value-based price
was most sensitive to utility values in the state of “improvement & tol-
erant” (Figure 3). An increase in utility by 0.1 resulted in higher value-
based prices of £27.60 and £31.05 for the scenarios of the “new iron”
reducing the risk of intolerance by 30% and 40%, respectively. How-
ever, a decrease in utility by 0.1 in three health states led to negative
value-based prices, reflecting the fact that the “new iron” would be in
the south-west quadrant of the cost-effectiveness plane.





Cost of “new iron” relative to the average cost of current iron preparations
x1 x2 x3 x4 x5 x6 x7 x8 x9 x10
-5% 0.0010 2.81 20.28 42.37 64.46 86.55 108.64 130.73 152.82 165.91 197.00
10% 0.0021 3.63 18.47 40.56 62.65 84.74 106.83 128.92 151.01 173.10 195.20
15% 0.0031 5.45 16.64 38.73 60.83 82.92 105.01 127.10 149.20 171.29 193.38
20% 0.0042 7.29 14.81 36.90 58.99 81.09 103.18 125.28 147.37 169.47 191.56
25% 0.0053 9.13 12.96 35.06 57.15 79.25 101.34 123.44 145.54 167.63 189.73
30% 0.0064 10.99 11.11 33.21 55.30 77.40 99.50 121.59 143.70 165.79 187.89
35% 0.0075 12.85 9.25 31.34 53.44 75.54 97.64 119.74 141.84 163.94 186.03
40% 0.0086 14.73 7.37 29.47 51.57 73.67 95.77 117.87 139.97 162.07 184.17
45% 0.0097 16.62 5.49 27.59 49.69 71.79 93.89 116.00 138.10 160.20 182.30
50% 0.0108 18.50 3.59 25.70 47.80 69.90 92.01 114.11 136.21 158.32 180.42
F IGURE 2 Value-based price
(£ per 28 tablets) of a hypothetical new oral iron
preparation, according to different relative
reductions in the probability of treatment
intolerance, and for the upper and lower bounds
of the willingness to pay threshold range
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The two-way analysis (Table 5) indicates zones of cost-
effectiveness and ineffectiveness for different combinations of
reductions in treatment intolerance and the cost of “new iron”
relative to current oral iron salts. With the exception of the
scenario of price parity and reduced intolerance, where “new iron”
would be expected to be, the ICERs indicated that higher prices
F IGURE 3 Tornado plots depicting
the sensitivity of the value-based price
(£ per 28 tablets) to changes in health state
utility (± 0.1). Vertical lines indicate the base-
case value-based prices at 30% (upper figure)
and 40% (lower figure) reduction in intolerance
TABLE 5 Two-way sensitivity analysis for the base-case, illustrating the dependency of the incremental cost-effectiveness ratio on the price
of “new iron” and effectiveness in terms of reduction in intolerance
% reduction in intolerance
Cost of “new iron” relative to the average cost of current iron preparations
x1 x2 x3 x4 x5 x6 x7 x8 x9 x10
5% 1790 20 074 41 938 63 802 85 665 107 530 129 394 151 257 164 213 194 985
10% 1718 8750 19 218 29 686 40 154 50 623 61 091 71 559 82 027 92 495
15% 1753 5350 12 453 19 556 26 659 33 762 40 865 47 968 55 071 62 174
20% 1731 3517 8764 14 012 19 260 24 507 29 755 35 002 40 250 45 497
25% 1720 2441 6602 10 763 14 924 19 084 23 245 27 406 31 567 35 728
30% 1714 1733 5180 8627 12 074 15 521 18 968 22 416 25 863 29 310
35% 1712 1231 4173 7116 10 058 13 001 15 943 18 886 21 828 24 770
40% 1711 856 3423 5989 8556 11 123 13 690 16 256 18 823 21 390
45% 1711 565 2841 5117 7393 9670 11 946 14 222 16 498 18 774
50% 1712 332 2377 4422 6466 8511 10 556 12 600 14 645 16 690
Cells shaded in green indicate incremental cost-effectiveness ratios (£/QALY gained; ICERs) that are below the £20 000 per QALY threshold; amber
indicates £20 000 to £30 000 per QALY; and red ≥£30 000 per QALY. Negative ICERs indicate incremental QALY gains and cost savings.
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may be set for “new iron” treatments with lower probabilities of
intolerance.
The results from the probabilistic sensitivity analysis, assuming
“new iron” is priced at 5 times the average cost of iron salts, and asso-
ciated with 40% reduced probability of treatment intolerance, indi-
cated that “new iron” is likely to be cost-effective, with 0.94 and 0.98
probabilities of being cost effective at willingness to pay thresholds of
£20 000 and £30 000 per QALY, respectively (Figure S1 in the
Supporting Information). At 10 times the cost of iron salts, and 30%
relative reduction in intolerance, the probability of “new iron” being
cost effective reduces to 0.21 and 0.65 for willingness to pay values
of £20 000 and £30 000 per QALY, respectively.
3.4 | Scenario analysis
In the alternative scenario where “new iron” is assumed not only to
reduce the probability of treatment intolerance, but also the probabil-
ity of residing in the hospitalisation health state, there were more
zones of cost-effectiveness for the same combination of reduction in
intolerance and prices of “new iron” (Table S2 in the Supporting
Information).
4 | DISCUSSION
Oral iron supplements are among the most frequently prescribed
medicines in primary care.3 Patients who experience ADRs, and are
therefore unable to tolerate treatment, may benefit from alternative
forms of oral iron, including non-iron salt supplements that are avail-
able or currently in development. The determination of value-based
prices provides a basis for assessing commercial viability for devel-
opers of new treatments, while also assisting the NHS in its horizon
scanning activities.
This analysis estimated that for new iron preparations that
reduce the relative risk of ADRs by 30–40%, the value-based price is
in the region of £10 and £13 per 28 tablets, or about 7–9 times the
price of present-day iron supplementation. At a modest price
increase (5-fold), there is a high probability (>90%) of a new iron
preparation being cost-effective if able to reduce the risk of treat-
ment intolerance by 40%. However, there is considerable uncertainty
over the extent to which new iron treatments might reduce gastroin-
testinal ADRs. Indeed, there are no head-to-head data of “new iron”
formulations versus ferrous salts that enable unbiased comparison of
clinical and cost-effectiveness. The value-based price reduces to
between £4.24 and £7.07 per 28 tablets for reductions of 10–20%
in ADRs.
Notwithstanding, these considerations are timely. In patients with
complex iron deficiency anaemia, such as in inflammatory bowel dis-
ease, there has been a push towards treatment with intravenous iron
therapy.29 This is because anaemia of chronic disease, which often
co-exists with iron deficiency anaemia, can lock down mobile iron and
result in poor absorption of oral iron. However, there are several
advantages to reducing outpatient visits for intravenous iron and even
a necessity to do so in the context of COVID-19.29 Hence, oral iron
approaches should be re-visited.29 This necessitates a better under-
standing of the value proposition within the complex array of supple-
mental iron options for hospital patients just as described above for
patients in primary healthcare.
Our analysis had strengths in addressing an important economic
question in the context of “new iron” and currently prescribed inex-
pensive, generic formulations of iron salts. Significant increases in the
cost of new treatments, beyond the value-based prices estimated
here, would impact adversely on the delivery of healthcare owing to
the opportunity costs (the marginal benefits forgone as a result of dis-
placing services to fund the new iron therapies would exceed the ben-
efits gained). Even if priced at the threshold, there would be no
immediate net benefits to the NHS.13 The value-based price should
therefore be considered as the maximally acceptable price.
The analysis benefited from using routine NHS data which pro-
vided accurate estimates of health state occupancy and healthcare
resource utilisation associated with the management of iron defi-
ciency anaemia. The CPRD includes patient electronic healthcare
records (EHR) collected routinely in primary care30 and is linked to
patients' HES data for accurate determination of hospital care.31 By
applying unit cost to items of resource use, the analysis considered
the actual costs of primary and secondary care services in the NHS.
There was, however, a limited evidence base relating to health
state utilities requiring assumptions that may not be generalisable to
the modelled population. Sensitivity analyses indicated that changes
in health state utilities within plausible ranges led to variation in
value-based prices. Further research on utilities in iron-deficiency
anaemia is warranted. The model structure was also limited by the
data available from EHR, and there were no randomised controlled
trial data on the relationship between dose and ADR,4 or the effec-
tiveness of sequential courses of treatment. Our analytic time horizon
was set to 12 months, which may not adequately capture all costs and
consequences, although it is recommended that treatment with ele-
mental iron should be limited to 3 months after iron deficiency is
corrected, this being considered sufficient to allow stores to be
replenished.32
Finally, we note that, currently in the UK, iron can be adminis-
tered parenterally when oral therapy is unsuccessful, for example if
patients cannot tolerate oral iron, or do not take it reliably.
Our economic analysis—very conservatively—did not compare new,
hypothetical oral iron preparations with parenteral iron, such as fer-
ric carboxymaltose, or iron dextran, sucrose or isomaltoside 1000.
This was principally because the CPRD data extraction was limited
to patients being prescribed oral iron supplementation. While there
are several budget impact analyses of parenteral iron for this clinical
indication, there are no economic analyses; had we considered par-
enteral products, a higher value-based price would likely have
resulted.
In conclusion, a significant proportion of patients with iron defi-
ciency anaemia are intolerant to oral iron salt preparations. This
increases the risk of non-adherence and treatment failure as well as
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impairing patients' health-related quality of life. The prospect of novel
oral iron preparations to reduce the incidence of ADRs warrants care-
ful analysis of how they are to be priced in the context of inexpensive
alternative generic iron salts. This value-based pricing analysis esti-
mates that new treatments may be cost-effective at prices that are
several-fold higher than existing oral iron salts, and which may be
attractive for commercial development while proving to be cost-
effective to the NHS.
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